AVP and Stroke: A meta-analysis revealed mean copeptin levels in different groups: stroke and non-stroke groups (19.8 ± 17.4 vs. 9.7 ± 6.6 pmol/L, respectively), good vs. poor outcome groups (12.0 ± 3.6 vs. 29.4 ± 14.5 pmol/L, respectively), and survive vs. non-survive stroke patients (13.4 ± 3.2 vs. 33.0 ± 12.3, respectively) (215), suggesting copeptin may guide the management of stroke patients.